1. Home
  2. ALKS

as 05-24-2024 3:30pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Founded: 1987 Country:
Ireland
Ireland
Employees: N/A City: DUBLIN 4
Market Cap: 4.1B IPO Year: 1991
Target Price: $36.40 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 2.55 EPS Growth: N/A
52 Week Low/High: $22.01 - $33.71 Next Earning Date: 05-01-2024
Revenue: $1,726,182,000 Revenue Growth: 54.01%
Revenue Growth (this year): -7.96% Revenue Growth (next year): 0.07%

ALKS Daily Stock ML Predictions

Stock Insider Trading Activity of Alkermes plc (ALKS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Nichols Christian Todd ALKS SVP, Chief Commercial Officer Mar 18 '24 Sell $28.10 10,417 $292,739.58 65,911 SEC Form 4
Parisi Samuel Joseph ALKS VP, Finance (Interim PAO) Feb 23 '24 Sell $29.65 2,559 $75,874.35 7,717 SEC Form 4
LAURENCIN CATO T ALKS Director Feb 15 '24 Sell $31.85 2,690 $85,676.50 15,169 SEC Form 4

Share on Social Networks: